Patents Assigned to JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INST
-
Publication number: 20120231523Abstract: A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.Type: ApplicationFiled: February 24, 2012Publication date: September 13, 2012Applicant: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INSTInventors: Kenji Soejima, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo
-
Publication number: 20120039863Abstract: A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.Type: ApplicationFiled: September 16, 2011Publication date: February 16, 2012Applicant: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INSTInventors: Kenji SOEJIMA, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo
-
Publication number: 20110117602Abstract: A human antibody that has a specific reactivity with multiple tumor cell lines including ATL cells and possesses both safety and therapeutic efficacy and a fragment of said antibody are provided. A human antibody and a fragment of said antibody that may recognize HLA-DR ? chain expressed on the surface of tumor cells were obtained. In particular, it was found that a dimer of scFv (diabody) of said antibody may induce potent apoptosis in cells expressing the HLA-DR ? chain. The antibody and a fragment of said antibody obtained in accordance with the present invention are useful for a detection reagent, a diagnostic and a medicament for protection or treatment of cancers including ATL and/or viral infectious diseases.Type: ApplicationFiled: November 18, 2008Publication date: May 19, 2011Applicants: KAGOSHIMA UNIVERSITY,, JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INSTInventors: Yuji Ito, Masanori Baba, Naomichi Arima, Yasuo Suda, Toshihiro Nakashima, Masaharu Torikai
-
Publication number: 20110059077Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human ?9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human ?9 integrin in the pathogenesis, whichType: ApplicationFiled: January 9, 2009Publication date: March 10, 2011Applicants: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INST., ASTELLAS PHARMA INC.Inventors: Kenji Uehara, Hirofumi Higuchi, Toshihiro Nakashima, Daisuke Ishikawa, Nobuchika Yamamoto, Hirotada Fujita, Fumihiko Sakai
-
Publication number: 20110014193Abstract: The present invention provides a humanized anti-human ?9 integrin antibody having improved activity and/or property as compared to donor mouse anti-human ?9 integrin antibody, namely, a humanized anti-human ?9 integrin antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 1 or the amino acid sequence shown by SEQ ID NO: 1 wherein one or several amino acids are substituted, deleted, inserted and/or added and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 61 or the amino acid sequence shown by SEQ ID NO: 61 wherein one or several amino acids are substituted, deleted, inserted and/or added, as well as a means for preventing or treating various diseases involving human ?9 integrin in their pathogenesis, which uses the antibody.Type: ApplicationFiled: July 9, 2009Publication date: January 20, 2011Applicant: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INSTInventors: Kenji Uehara, Hirofumi Higuchi, Toshihiro Nakashima, Daisuke Ishikawa, Nobuchika Yamamoto, Hirotada Fujita, Fumihiko Sakai
-
Publication number: 20100285568Abstract: A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.Type: ApplicationFiled: October 8, 2008Publication date: November 11, 2010Applicant: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INSTInventors: Kenji Soejima, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo
-
Publication number: 20100267816Abstract: A human anti-amyloid ? peptide (hereinafter referred to as “A?”) antibody that binds to A? to thereby inhibit aggregation of A? molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-A? antibody, strongly reacts with A? to thereby inhibit its aggregation and hence may be used as a medicament for the prophylaxis and treatment of Alzheimer dementia.Type: ApplicationFiled: June 2, 2010Publication date: October 21, 2010Applicant: JURIDICAL FDN THE CHEMO-SERO-THERAPEUTIC RES INSTInventors: Kazuhisa SUGIMURA, Toshihiro Nakashima